The Catalyst


07.31.13 | By Preet Bilinski

The human brain, despite weighing just 3 pounds, contains over 100 billion neurons -- to say that it's complex is an understatement. These neurons are responsible for receiving messages and forwarding them to the appropriate parts of the brain, which in turn control everything we do.

07.30.13 | By Sascha Haverfield

The assessment of benefits and risks is critical in the development of new medicines.

07.30.13 | By John Castellani

Every person is unique, and so are the challenges they face when it comes to their health.

07.25.13 | By Randy Burkholder

On Monday, the Personalized Medicine Coalition convened leaders from the field on Capitol Hill to discuss the promise of personalized medicine and the implications for policy-makers. A number of important issues were raised (more on that in my next post), but the highlight was remarks by Stephanie Haney. Stephanie is a lung cancer patient and mother of two who said she is alive today thanks to a novel personalized medicine.

07.24.13 | By John Castellani

The biopharmaceutical industry is firmly committed to enhancing public health through responsible reporting and publication of clinical research and safety information.

07.24.13 | By Jay Taylor

Today, PhRMA President and CEO John Castellani testified before the House Energy and Commerce subcommittee on Commerce, Manufacturing and Trade about an ambitious new free trade agreement being negotiated between the United States and the European Union.

07.23.13 | By Jay Taylor

This week, negotiators conclude the 18th round of Trans-Pacific Partnership (TPP) negotiations in Malaysia. The agreement, which includes Malaysia and 11 other nations, not only provides the United States with an entrée into the Asia Pacific region, but also opens new markets for all participating countries.


The United States faces a growing number of health care challenges.


Big storms – like Sandy, like Katrina – happen. The toll can be devastating.  Proper preparation to meet the human, logistical and supply-chain problems that come along with a big storm is critical.

07.22.13 | By John Castellani

Last week’s ‘Conversations’ question “What steps should the U.S. take to protect and strengthen IP rights domestically and overseas?” prompted interesting responses from the U.S.


The biopharmaceutical community has made tremendous progress in recent years developing innovative treatments for chronic conditions, thanks to advancements in science and medicine.  Not only do these advancements improve people’s lives every day, they also provide hope that we may one day be able to prevent or cure diseases like Alzheim


Today Show contributor Linda Carroll wrote a great article about the importance of detecting Alzheimer's disease earlier in life.


This week in Malaysia, the United States continues Trans-Pacific Partnership (TPP) negotiations with many of its most important Asia-Pacific trading partners. As we’ve discussed extensively on the Catalyst, through TPP the U.S.

07.16.13 | By Preet Bilinski

I’m not talking about a broken heart from love, but rather from heart disease.

07.15.13 | By John Castellani

A chronic disease is detrimental to more than just the person who has it – its impact ripples through the health care system and economy as a whole. According to research by the Robert Wood Johnson Foundation, 80 cents of every dollar spent on health care in the United States goes to treat chronic disease.


The increasing burden of chronic diseases, as well as potential solutions to the problem, were a major focus for us this week.


From cancer and diabetes to heart disease and hypertension, prevalence of chronic disease in America has reached epidemic proportions. In the U.S., 75 percent of our health care dollars go toward its treatment.

07.09.13 | By Stephanie Fischer

It was one year ago today that the Food and Drug Administration Safety and Innovation Act (FDASIA) was signed into law, reauthorizing the Prescription Drug User Fee Act (

07.09.13 | By John Castellani

Every day, our industry works to develop new medicines that extend and improve the quality of life for patients. As the Baby Boom generation enters retirement age, one critical health care issue that we must address is how to keep our nation’s seniors healthy. It’s a topic that I come across regularly in my role at PhRMA.


Research shows that properly adhering to medications is a major challenge, but patients who take their medications as prescribed are more likely to have better outcomes.